Eris Lifesciences Q4 FY26 Results: PAT Rs 280 Cr
- May 20, 2026
- Posted by: Kashish Aggarwal
- Category: News
Eris Lifesciences Q4 FY26 results were declared on May 20, 2026. Eris Lifesciences reported PAT of Rs 280 crore for the quarter ended March 31, 2026, up 174% YoY compared to Rs 102 crore in Q4 FY25. Revenue from operations stood at Rs 757 crore, up 7% YoY. Gross profit was Rs 204 crore (up 16% YoY). The results are on a Consolidated basis. Eris Lifesciences is a Branded Pharmaceuticals company listed on Indian stock exchanges.
Click Here – Get Free Investment Predictions
Eris Lifesciences Q4 FY26 Financial Highlights
| Metric | Q4 FY26 (Rs Cr) | Q4 FY25 (Rs Cr) | YoY Change |
|---|---|---|---|
| Revenue | 757 | 705 | +7% |
| Gross Profit | 204 | 175 | +16% |
| Net Profit | 280 | 102 | +174% |
| Basis | Consolidated | ||
Note: Exceptional quarter: PAT surged 174% YoY to Rs 280 crore on revenue of Rs 757 crore (+7% YoY). Gross profit +16% to Rs 204 crore. Eris Lifesciences Q4 FY26 results declared May 20, 2026. Verify from BSE/NSE audited filings.
Eris Lifesciences Q4 FY26 Performance Analysis
The Eris Lifesciences Q4 FY26 results reflect the company’s operational performance in the January to March 2026 quarter. The quarter demonstrates a meaningful improvement in profitability. Eris Lifesciences operates in the Branded Pharmaceuticals space, a sector shaped by domestic consumption trends, input costs, and India’s macro environment in FY26.
The 174% YoY PAT growth in Eris Lifesciences Q4 FY26 reflects operational improvements, better cost management, and revenue scale benefits.
Screen the best stocks on the Univest Screener.
Key Factors Driving Eris Lifesciences Q4 FY26 Results
Revenue Performance in Q4 FY26
Eris Lifesciences Q4 FY26 revenue of Rs 757 crore was up 7% YoY. Revenue was broadly stable, reflecting a steady operating environment for the Branded Pharmaceuticals business.
Profitability and Margin Trends
The Eris Lifesciences Q4 FY26 PAT of Rs 280 crore (up 174% YoY) reflects strong operating leverage and margin expansion in the Branded Pharmaceuticals business.
India Macro Tailwinds in Q4 FY26
The January to March 2026 quarter benefited from India’s GDP growth above 6.5%, strong government capital expenditure, and resilient urban and rural consumption. The RBI’s accommodative policy stance supported demand conditions across consumer and industrial sectors. For Eris Lifesciences, operating in the Branded Pharmaceuticals space, this macro environment provided a constructive demand backdrop during the quarter.
FY27 Outlook for Eris Lifesciences
Following Eris Lifesciences Q4 FY26 results, investors will track management commentary on FY27 revenue guidance, margin trajectory, capex plans, and competitive positioning. The Branded Pharmaceuticals sector continues to benefit from India’s structural growth story, rising middle-class consumption, and infrastructure investment cycle.
Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.
Frequently Asked Questions on Eris Lifesciences Q4 FY26
What is Eris Lifesciences Q4 FY26 net profit?
Ans. Eris Lifesciences Q4 FY26 PAT of Rs 280 crore, up 174% YoY from Rs 102 crore in Q4 FY25. Results declared May 20, 2026, on a Consolidated basis.
What is Eris Lifesciences Q4 FY26 revenue?
Ans. Eris Lifesciences Q4 FY26 revenue from operations was Rs 757 crore, up 7% YoY. Gross profit was Rs 204 crore (up 16% YoY).
When were Eris Lifesciences Q4 FY26 results declared?
Ans. Eris Lifesciences Q4 FY26 results were declared on May 20, 2026, at the board of directors meeting approving audited financial statements for Q4 and full-year FY26.
Is Eris Lifesciences a good investment after Q4 FY26 results?
Ans. Investment decisions require individual assessment of fundamentals, valuation, risk tolerance, and investment horizon. This article is for educational purposes. Consult a SEBI-registered financial advisor before investing in Eris Lifesciences.
Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Verify all figures from BSE/NSE filings. Consult a SEBI-registered financial advisor.
